Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring

FHS
May 16, 2024
11:47 am

Rapid Novor Inc., a global leader in mass spectrometry (MS)-based antibody protein sequencing, today announced that the first patient has been enrolled in a new clinical study titled ‘Clinical evaluation of EasyM™ for disease response analysis in newly diagnosed MM patients (NDMM)’.

Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines

By Dr. Andrea Pfeifer, CEO of AC Immune SA The clinical success we’ve recently seen with two monoclonal antibodies that target the protein amyloid beta

June 13, 2023

How climate change is driving a global epidemic of immune health problems, and how to stop it

Many of the effects of climate change play out at a very large scale: Heatwaves that grip entire continents. Flooding that submerges vast swaths of

April 4, 2024

FDA delays PDUFA date for Rocket’s rare white blood cell disorder gene therapy

The FDA’s decision on Rocket Pharmaceuticals’ autologous gene therapy for a rare white blood cell disorder has been pushed back by three months to June

February 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.